Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Update of the phase 1/2 EVOLVE study (NCT03430011) Meeting Abstract
| Authors: | Mailankody, S.; Jakubowiak, A. J.; Htut, M.; Costa, L. J.; Lee, K.; Ganguly, S.; Kaufman, J. L.; Siegel, D. S. D.; Bensinger, W.; Cota, M.; Doerr, T.; DeVries, T.; Wong, S. W. K. |
| Abstract Title: | Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Update of the phase 1/2 EVOLVE study (NCT03430011) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368303290 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.8504 |
| Notes: | Meeting Abstract: 8504 -- Source: Wos |
